Dec 02, 2017 - Shares have risen a decent bit since my initial entries, but I believe 2018 holds substantially more upside ahead.Below I provide a recap of the bullish thesis and recent events.After its September se
Dec 11, 2017 - Investors need to pay close attention to Array BioPharma (ARRY) stock based on the movements in the options market lately.
Dec 19, 2017 - While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018.Argenx received a very large price hike from an analyst.Global Blood Therap
Dec 19, 2017 - Array Biopharma Inc (ARRY) CEO Ron Squarer Sold $8.9 million of Shares, Stocks: ARRY, release date:Dec 19, 2017
Dec 21, 2017 - I remind readers to check out my recent interview with Seeking Alpha Editor Steve Brown for my thoughts on the year ahead and themes that could work.Perceptive Advisors' stake in Global Blood Therape
Dec 26, 2017 - Amgen plans to repatriate some of its cash holdings kept outside the U.S. Roche acquired Ignyta, paying premium of more than 70%. Agile tumbled nearly 50% on CRL.
Jan 04, 2018 - Ardelyx announced a significant drop in diarrhea incidence. Omeros reached an agreement with FDA on design of Phase 3 trial for OMS 721 in IgN. Allergan announced that it will cut more than 1,000 jobs
Jan 09, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with this event.
Jan 22, 2018 - Stifel issues rating change for ARRY
Jan 22, 2018 - Researchers say they are "very excited" about the clinical results of Array BioPharma Inc.'s metastatic colorectal cancer drug.
The Boulder biotech announced Saturday that in a clinical test of 30 patients, the results showed "substantial improvements compared to several separate historical published standard of care benchmarks for this population."
"We are very excited about these safety lead-in results, which show both an unprecedented progression-free survival and overall response rate in patients…